drugset
drugset / Trial / NCT00482053

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

NCT00482053 ↗

Phase 2 Terminated 3 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional transplantation regimen.

Timeline

Start
2006-10
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.5 mg/kg —
Background Acetaminophen Small molecule 650 mg Oral
Background Cyclophosphamide Other / unclassified 100 mg/kg —
Background Cyclosporine Peptide 5 mg/kg —
Background Diphenhydramine Unknown 50 mg Intravenous
Background Etoposide Small molecule 60 mg/kg —
Background Etoposide Small molecule 2 g —
Background Hydrocortisone Other / unclassified 100 mg Intravenous
Background Methylprednisolone Other / unclassified 1 mg/kg —
Background Mycophenolate Mofetil Small molecule 15 mg/kg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background carmustine Small molecule 15 mg/kg —
Background filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous
Background filgrastim Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications

diffuse large B-cell lymphoma